drugset / Trial / NCT05506332
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.
Timeline
- Start
- 2022-07-15
- Primary completion
- 2024-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MERCAPTOPURINE ANHYDROUS | Small molecule | 100 mg | — |
| Subject | Venetoclax | Small molecule | 600 mg | — |